NCT01903330 2025-03-05ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma MultiformeEpitopoietic Research CorporationPhase 2 Active not recruiting84 enrolled
NCT02052648 2024-03-27Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain TumorsLumos PharmaPhase 1/2 Completed160 enrolled 21 charts
NCT02330562 2022-06-08Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCelgenePhase 1/2 Completed121 enrolled 27 charts